Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives $35.71 Consensus Target Price from Analysts

Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) have received a consensus recommendation of “Buy” from the nine brokerages that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among analysts that have covered the stock in the last year is $35.71.

DAWN has been the topic of a number of analyst reports. HC Wainwright reiterated a “buy” rating and set a $40.00 price objective on shares of Day One Biopharmaceuticals in a research note on Thursday, October 31st. Needham & Company LLC reiterated a “buy” rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. JPMorgan Chase & Co. cut their price objective on shares of Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. Finally, TD Cowen upgraded shares of Day One Biopharmaceuticals to a “strong-buy” rating in a research note on Monday, November 4th.

Day One Biopharmaceuticals Stock Down 0.6 %

Shares of NASDAQ:DAWN opened at $13.84 on Thursday. The firm has a market capitalization of $1.40 billion, a PE ratio of -13.44 and a beta of -1.51. The company has a 50-day moving average price of $14.32 and a two-hundred day moving average price of $14.13. Day One Biopharmaceuticals has a twelve month low of $11.51 and a twelve month high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its quarterly earnings data on Wednesday, October 30th. The company reported $0.38 EPS for the quarter, topping the consensus estimate of ($0.20) by $0.58. The business had revenue of $93.76 million during the quarter, compared to the consensus estimate of $15.05 million. During the same period last year, the business posted ($0.54) earnings per share. Analysts anticipate that Day One Biopharmaceuticals will post -0.88 earnings per share for the current fiscal year.

Insider Transactions at Day One Biopharmaceuticals

In related news, insider Samuel C. Blackman sold 11,245 shares of Day One Biopharmaceuticals stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $16.03, for a total value of $180,257.35. Following the transaction, the insider now owns 1,085,790 shares in the company, valued at $17,405,213.70. This trade represents a 1.03 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last three months, insiders sold 51,745 shares of company stock worth $775,867. 8.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Several institutional investors have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Day One Biopharmaceuticals by 38.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company’s stock worth $51,000 after buying an additional 1,002 shares during the period. SteelPeak Wealth LLC increased its stake in shares of Day One Biopharmaceuticals by 9.8% during the third quarter. SteelPeak Wealth LLC now owns 17,400 shares of the company’s stock valued at $242,000 after purchasing an additional 1,550 shares in the last quarter. Handelsbanken Fonder AB raised its stake in Day One Biopharmaceuticals by 16.9% during the third quarter. Handelsbanken Fonder AB now owns 27,000 shares of the company’s stock valued at $376,000 after buying an additional 3,900 shares during the last quarter. Hennion & Walsh Asset Management Inc. raised its position in shares of Day One Biopharmaceuticals by 8.6% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 64,359 shares of the company’s stock worth $887,000 after purchasing an additional 5,070 shares during the last quarter. Finally, Martingale Asset Management L P raised its holdings in Day One Biopharmaceuticals by 9.6% in the third quarter. Martingale Asset Management L P now owns 71,304 shares of the company’s stock worth $993,000 after buying an additional 6,219 shares during the last quarter. 87.95% of the stock is currently owned by hedge funds and other institutional investors.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.